000 01611 a2200457 4500
005 20250516143712.0
264 0 _c20140124
008 201401s 0 0 eng d
022 _a1559-0755
024 7 _a10.1007/s12026-013-8407-x
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aColoma Bazán, Emmanuel
245 0 0 _aDiscontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative.
_h[electronic resource]
260 _bImmunologic research
_cJul 2013
300 _a358-61 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aAntibodies, Anticardiolipin
_xblood
650 0 4 _aAnticoagulants
_xtherapeutic use
650 0 4 _aAntiphospholipid Syndrome
_xcomplications
650 0 4 _aFemale
650 0 4 _aFollow-Up Studies
650 0 4 _aHumans
650 0 4 _aLupus Coagulation Inhibitor
_xblood
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aPregnancy
650 0 4 _aPregnancy Complications, Hematologic
_xdiagnosis
650 0 4 _aRecurrence
650 0 4 _aRetrospective Studies
650 0 4 _aThrombosis
_xetiology
650 0 4 _aWithholding Treatment
650 0 4 _aYoung Adult
700 1 _aDonate López, Carolina
700 1 _aMoreno Lozano, Pedro
700 1 _aCervera, Ricard
700 1 _aEspinosa, Gerard
773 0 _tImmunologic research
_gvol. 56
_gno. 2-3
_gp. 358-61
856 4 0 _uhttps://doi.org/10.1007/s12026-013-8407-x
_zAvailable from publisher's website
999 _c22652150
_d22652150